Literature DB >> 21887788

IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells.

Qianting Yang1, Gang Li, Yibei Zhu, Lin Liu, Elizabeth Chen, Hēth Turnquist, Xueguang Zhang, Olivera J Finn, Xinchun Chen, Binfeng Lu.   

Abstract

The effector functions of CD8(+) T cells are influenced by tissue inflammatory microenvironments. IL-33, a member of the IL-1 family, acts as a danger signal after its release during cell necrosis. The IL-33/ST2 axis has been implicated in various Th2 responses. Its role in CD8(+) T-cell-mediated immune response is, however, not known. Here we find that type 1 cytotoxic T (Tc1) cells cultured in vitro unexpectedly express high levels of the IL-33 receptor ST2. Interestingly, the expression of ST2 in Tc1 cells is dependent on T-bet, a master Th1/Tc1 transcription factor. In addition, IL-33 enhances TCR-triggered IFN-γ production. IL-33 together with IL-12 can stimulate IFN-γ production in Tc1 cells. Moreover, IL-33 synergizes with IL-12 to promote CD8(+) T-cell effector function. The synergistic effect of IL-33 and IL-12 is partly mediated by Gadd45b. Together, these in vitro data establish a novel role of IL-33 in promoting effector type 1 adaptive immune responses.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21887788      PMCID: PMC3332117          DOI: 10.1002/eji.201141629

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  49 in total

1.  A novel transcription factor, T-bet, directs Th1 lineage commitment.

Authors:  S J Szabo; S T Kim; G L Costa; X Zhang; C G Fathman; L H Glimcher
Journal:  Cell       Date:  2000-03-17       Impact factor: 41.582

2.  Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules.

Authors:  Espen S Baekkevold; Myriam Roussigné; Takeshi Yamanaka; Finn-Eirik Johansen; Frode L Jahnsen; François Amalric; Per Brandtzaeg; Monique Erard; Guttorm Haraldsen; Jean-Philippe Girard
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

3.  Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes.

Authors:  W L Chan; N Pejnovic; C A Lee; N A Al-Ali
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

4.  IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production.

Authors:  J Yang; H Zhu; T L Murphy; W Ouyang; K M Murphy
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

5.  Kinetic analysis of genomewide gene expression reveals molecule circuitries that control T cell activation and Th1/2 differentiation.

Authors:  Binfeng Lu; Panayiotis Zagouras; James E Fischer; Junfeng Lu; Baiyong Li; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

6.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

7.  Gadd45beta is important for perpetuating cognate and inflammatory signals in T cells.

Authors:  Binfeng Lu; Anthony F Ferrandino; Richard A Flavell
Journal:  Nat Immunol       Date:  2003-12-14       Impact factor: 25.606

8.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.

Authors:  Susan M Kaech; Joyce T Tan; E John Wherry; Bogumila T Konieczny; Charles D Surh; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-11-16       Impact factor: 25.606

9.  Interferon gamma stabilizes the T helper cell type 1 phenotype.

Authors:  Y Zhang; R Apilado; J Coleman; S Ben-Sasson; S Tsang; J Hu-Li; W E Paul; H Huang
Journal:  J Exp Med       Date:  2001-07-16       Impact factor: 14.307

10.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  82 in total

1.  Quantitative phosphoproteomic analysis of IL-33-mediated signaling.

Authors:  Sneha M Pinto; Raja Sekhar Nirujogi; Pamela Leal Rojas; Arun H Patil; Srikanth S Manda; Yashwanth Subbannayya; Juan Carlos Roa; Aditi Chatterjee; T S Keshava Prasad; Akhilesh Pandey
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

2.  IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis.

Authors:  Yuejin Liang; Panpan Yi; Denley Ming Kee Yuan; Zuliang Jie; Zakari Kwota; Lynn Soong; Yingzi Cong; Jiaren Sun
Journal:  Cell Mol Immunol       Date:  2018-02-05       Impact factor: 11.530

Review 3.  Interleukin 33: a switch-hitting cytokine.

Authors:  Daniel O Villarreal; David B Weiner
Journal:  Curr Opin Immunol       Date:  2014-04-22       Impact factor: 7.486

4.  Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.

Authors:  Xin Gao; Xuefeng Wang; Qianting Yang; Xin Zhao; Wen Wen; Gang Li; Junfeng Lu; Wenxin Qin; Yuan Qi; Fang Xie; Jingting Jiang; Changping Wu; Xueguang Zhang; Xinchun Chen; Heth Turnquist; Yibei Zhu; Binfeng Lu
Journal:  J Immunol       Date:  2014-11-26       Impact factor: 5.422

Review 5.  Implications for Interleukin-33 in solid organ transplantation.

Authors:  Quan Liu; Hēth R Turnquist
Journal:  Cytokine       Date:  2013-03-27       Impact factor: 3.861

Review 6.  Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.

Authors:  Binfeng Lu; Min Yang; Qingqing Wang
Journal:  J Mol Med (Berl)       Date:  2016-02-27       Impact factor: 4.599

7.  ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice.

Authors:  Julia E Rood; Sheila Rao; Michele Paessler; Portia A Kreiger; Niansheng Chu; Erietta Stelekati; E John Wherry; Edward M Behrens
Journal:  Blood       Date:  2015-10-30       Impact factor: 22.113

8.  Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity.

Authors:  Daniel O Villarreal; Megan C Wise; Jewell N Walters; Emma L Reuschel; Min Joung Choi; Nyamekye Obeng-Adjei; Jian Yan; Matthew P Morrow; David B Weiner
Journal:  Cancer Res       Date:  2014-01-21       Impact factor: 12.701

9.  T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses.

Authors:  Claudia Baumann; Weldy V Bonilla; Anja Fröhlich; Caroline Helmstetter; Michael Peine; Ahmed N Hegazy; Daniel D Pinschewer; Max Löhning
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-17       Impact factor: 11.205

10.  Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice.

Authors:  Chuan Qiu; Yan Li; Mingcai Li; Min Li; Xiaojin Liu; Charles McSharry; Damo Xu
Journal:  Immunology       Date:  2013-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.